A Multi-omics Study of Epithelial Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03742856|
Recruitment Status : Recruiting
First Posted : November 15, 2018
Last Update Posted : November 15, 2018
|Condition or disease||Intervention/treatment|
|Epithelial Ovarian Cancer Tumor Invasiveness Whole Exome Sequencing Transcriptomics Metabolomics Tumorigenesis||Combination Product: A multi-omics analysis|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||A Multi-omics Study on the Invasiveness of Epithelial Ovarian Cancer|
|Actual Study Start Date :||November 10, 2018|
|Estimated Primary Completion Date :||November 23, 2020|
|Estimated Study Completion Date :||November 23, 2020|
- Combination Product: A multi-omics analysis
A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
- Frequencies of somatic driving mutations [ Time Frame: Two years ]The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes.
- Frequencies of alteration of RNA expression [ Time Frame: Two years ]The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes.
- Frequencies of alteration of protein expression and signal pathway [ Time Frame: Two years ]The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes.
- Progression-free survival [ Time Frame: Five years ]Progression-free survival between patients with differential expressed multi-omics will be compared.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03742856
|Contact: Lei Li, M.D.||13911988831 ext firstname.lastname@example.org|
|Beijing, Beijing, China, 100730|
|Contact: Lei Li, MD 13911988831 ext 86 email@example.com|
|Principal Investigator:||Lei Li, M.D.||Peking Union Medical College Hospital|